<img src="https://trc.taboola.com/1321591/log/3/unip?en=page_view" width="0" height="0" style="display:none">
Fact Check Library

Fact Check with Logically.

Download the Free App Today

false
false

CLAIM ID

9c26df33

Lexatrade a genuine trading platform.

LexaTrade runs its trading business without the required permit or authorization and is registered offshore. It is risky to use their platform.

LexaTrade runs its trading business without the required permit or authorization and is registered offshore. It is risky to use their platform.LexaTrade is a forex broker owned by Swissone Group Ltd. for trading in indices, commodities, and forex. Anyone can easily register and open an account to start trading right away on their website.

The Polish Financial Supervision Authority has put out a warning on its website, which includes the name of LexaTrade and mentions that the entity is not registered in Poland. The proceedings have been initiated under Art. 178 of the Act on Trading in Financial Instruments.

The company’s address is in St. Vincent and the Grenadines, which is an offshore zone. Forex brokers from offshore are not regulated by any government bodies; if the broker goes bankrupt or decides to shut down, there is no guarantee on the funds invested.

Further, the company’s website shows a leverage ratio of 1:200, which is considered high. Traders choosing brokers that offer high leverage are at risk of losing their funds. The odds of losing money is very high for someone trading using high leverage. Moreover, offshore brokers like LexaTrade cannot operate on any regulated financial market such as the European Union, the UK, USA, Canada, Japan, Australia, etc.

Have a question or correction on one of our fact-checks?

If you think a claim has been misjudged or requires correction, please send us evidence to support your error claim. We will revisit our evidence and verdict and conduct additional research to verify new information.

Fact Check of the Day

misleading

397 children were diagnosed with heart inflammation after receiving Pfizer’s COVID-19 vaccine in U.S.